Jed Latkin - ProPhase Labs Chief Department
| PRPH Stock | USD 0.77 0.02 2.67% |
Executive
Jed Latkin is Chief Department of ProPhase Labs
| Age | 50 |
| Address | 711 Stewart Avenue, Garden City, NY, United States, 11530 |
| Phone | 215 345 0919 |
| Web | https://www.prophaselabs.com |
ProPhase Labs Management Efficiency
The company has return on total asset (ROA) of (0.2298) % which means that it has lost $0.2298 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5092) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -0.21. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.29. As of now, ProPhase Labs' Other Current Assets are decreasing as compared to previous years. The ProPhase Labs' current Intangible Assets is estimated to increase to about 12.9 M, while Total Current Assets are projected to decrease to under 27.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cory Anderson | Neuronetics | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Robbie Lunt | Biodesix | N/A | |
| Hao Liu | Burning Rock Biotech | 50 | |
| Shannon Shoemaker | Psychemedics | 38 | |
| Mary Mooney | DarioHealth Corp | N/A | |
| Omar MD | DarioHealth Corp | N/A | |
| Jeffrey Black | Exagen Inc | 55 | |
| Austin Aerts | Sera Prognostics | 37 | |
| Michael Weisenhoff | Psychemedics | 34 | |
| Benjamin JD | Sera Prognostics | 45 | |
| Steven Springmeyer | Biodesix | N/A | |
| Hannah Bible | Star Equity Holdings | 44 | |
| Brian Fisher | Enzo Biochem | 53 | |
| Scott Jarchow | Star Equity Holdings | N/A | |
| Daniella Mehalik | Psychemedics | 34 | |
| Claudia Levi | DarioHealth Corp | N/A | |
| Rick Grubbs | Neuronetics | N/A | |
| Lisa MetznerRosas | Neuronetics | N/A | |
| Matthew Kupferberg | Enzo Biochem | 58 | |
| Kathleen Hoffman | Sotera Health Co | N/A | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.23 |
ProPhase Labs Leadership Team
Elected by the shareholders, the ProPhase Labs' board of directors comprises two types of representatives: ProPhase Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProPhase. The board's role is to monitor ProPhase Labs' management team and ensure that shareholders' interests are well served. ProPhase Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProPhase Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Billy White, Consultant | ||
| Lance Bisesar, Corporate Controller | ||
| Robert Morse, Principal Controller | ||
| Ted Karkus, Chairman and CEO | ||
| Sergio Miralles, Executive Diagnostics | ||
| Kamal Obbad, Senior Genomics | ||
| Jason Karkus, President Diagnostics | ||
| Monica Brady, Principal Financial Officer & Principal Accounting Officer | ||
| Jed Latkin, Chief Department | ||
| Alice Lioi, EVP BioPharma |
ProPhase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProPhase Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (3.16) % | ||||
| Current Valuation | 47.47 M | ||||
| Shares Outstanding | 23.87 M | ||||
| Shares Owned By Insiders | 14.33 % | ||||
| Shares Owned By Institutions | 7.63 % | ||||
| Number Of Shares Shorted | 245.65 K | ||||
| Price To Earning | 6.59 X |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.